BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing (PRNewswire) - Nov 11, 2024 - "BrainStorm Cell Therapeutics Inc...today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc...to manufacture NurOwn for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement. Under the terms of the proposed agreement, Pluri will provide GMP-compliant manufacturing of NurOwn at its facilities in Israel...BrainStorm plans to hold a conference call for investors later in Q4 2024, during which it will provide further updates on the NurOwn Phase 3 clinical program."
Clinical • Commercial • Amyotrophic Lateral Sclerosis • CNS Disorders
|